Injectable vs. topical vs. oral: how route changes the evidence
The same compound can have solid evidence one way and almost none another. Route of administration is part of the evidence, not a footnote.
Peptides are fragile molecules, and how you deliver one changes what happens to it, and therefore what the research on it can support. A result from an injected study says little about a cream, and a cosmetic study says little about a pill. This chart lays the three routes side by side.
Why route is part of the evidence
A peptide taken by mouth usually meets digestive enzymes that break it down before much reaches the bloodstream, which is why oral peptide evidence is sparse and limited to a few specifically engineered exceptions. Injected, the same peptide reaches circulation reliably, which is why most peptide research uses that route. Applied to skin, it acts largely where it is placed. These are different exposures, so they are different questions.
| Route | Reaches bloodstream | Where the evidence sits |
|---|---|---|
| Injectable (SC/IM) | High, reliable | Most peptide research |
| Topical | Minimal, acts locally | Narrow (e.g. GHK-Cu skin) |
| Oral | Low unless engineered | Sparse, route-specific |
The female-specific catch differs by route
Each route carries its own women's-evidence gap. For injectables, the dosing figures in circulation are largely male-derived. For topicals, cosmetic studies often skew female yet rarely report sex-stratified outcomes, GHK-Cu is the clearest case. For oral products, the gut is exactly where a documented female interaction lives: GLP-1 drugs slow gastric emptying, which can reduce absorption of oral contraceptives, a label-level interaction for tirzepatide.
When you read a claim about a compound, check the route first. If the research was topical and the product is injectable, or the reverse, treat the evidence as not yet established for the form in front of you. That mismatch is one of the most common ways thin evidence looks fuller than it is.
For the oral-absorption interaction in detail, see How GLP-1 receptor agonists work.
Compounds referenced
Get the guides
A note when each guide goes live. Clear science, written for women.
Sources
- Pharmacokinetics of peptide administration routes: subcutaneous/intramuscular bioavailability versus oral degradation in the GI tract and topical local action.
- MOUNJARO (tirzepatide) U.S. Prescribing Information, oral hormonal contraceptive interaction via delayed gastric emptying. View source ↗
Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe. Some outbound links are affiliate links.